Centessa Pharmaceuticals plc · Q2 2021 earnings

Briefing

Centessa reported financial results for the second quarter ended June 30, 2021, and provided a review of recent accomplishments.

Centessa Pharmaceuticals announced second quarter 2021 financial results, highlighting the successful completion of an initial public offering, which raised gross proceeds of $379.5 million. The company is advancing its portfolio of 16 clinical and preclinical programs and has strengthened its leadership team with key industry executives.

• Successfully completed an initial public offering raising gross proceeds of $379.5 million.
• Centessa leadership team strengthened through appointment of key industry executives.
• Programs across Centessa portfolio continue to progress, with new data releases and/or trial initiations anticipated from ApcinteX, Palladio, Z-Factor and Pega-One in the second half of 2021.
• Cash and cash equivalents were $613.8 million as of June 30, 2021.

Headline financials

Revenue & EPS history

Based on the current, non-risk-adjusted operating plan, the Company expects the cash and cash equivalents as of June 30, 2021, to fund its operations until the end of 2023.